Immunology of COVID-19: Current State of the Science #MMPMID32505227
Vabret N; Britton GJ; Gruber C; Hegde S; Kim J; Kuksin M; Levantovsky R; Malle L; Moreira A; Park MD; Pia L; Risson E; Saffern M; Salomé B; Esai Selvan M; Spindler MP; Tan J; van der Heide V; Gregory JK; Alexandropoulos K; Bhardwaj N; Brown BD; Greenbaum B; Gümü? ZH; Homann D; Horowitz A; Kamphorst AO; Curotto de Lafaille MA; Mehandru S; Merad M; Samstein RM
Immunity 2020[Jun]; 52 (6): 910-41 PMID32505227show ga
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an unprecedented effort from the scientific community to understand the biological underpinning of COVID19 pathophysiology. In this Review, we summarize the current state of knowledge of innate and adaptive immune responses elicited by SARS-CoV-2 infection and the immunological pathways that likely contribute to disease severity and death. We also discuss the rationale and clinical outcome of current therapeutic strategies as well as prospective clinical trials to prevent or treat SARS-CoV-2 infection.